Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals Inc (NQ: MIRM )

38.46 -0.72 (-1.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mirum Pharmaceuticals Inc

< Previous 1 2 3 4 Next >
Analyst Expectations For Mirum Pharmaceuticals's Future
Via Benzinga
MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Beats Revenue for Q2 2024
MIRM stock results show that Mirum Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Analyst Ratings For Mirum Pharmaceuticals
Via Benzinga
Analyst Ratings For Mirum Pharmaceuticals
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies
Mirum Pharmaceuticals announced promising interim results from Phase 2b studies of volixibat for primary biliary cholangitis and primary sclerosing cholangitis. Significant improvements in pruritus and... 
Via Benzinga
Aaron's, Nvidia, Mirum Pharmaceuticals, Primo Water And Other Big Stocks Moving Higher On Monday
Via Benzinga
MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
MIRM stock results show that Mirum Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
$5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. 
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Mirum Pharmaceuticals
Via Benzinga
Critical Insights From Mirum Pharmaceuticals Analyst Ratings: What You Need To Know
Via Benzinga
Mirum Pharmaceuticals: Q4 Earnings Insights
Via Benzinga
FDA Approves Mirum's Livmarli For Liver Disease In Kids As Young As 5 Years: Analyst Bullish On Label Expansion Strategy
FDA approves Livmarli by Mirum Pharmaceuticals for cholestatic pruritus in PFIC patients ≥5 years old. Data from Phase 3 MARCH study. Analysts bullish on broader coverage in 2024, with price target... 
Via Benzinga
Exposures Product Safety
Preview: Mirum Pharmaceuticals's Earnings
Via Benzinga
Where Mirum Pharmaceuticals Stands With Analysts
Via Benzinga
Veradigm, Aehr Test Systems, Saratoga Investment And Other Big Stocks Moving Lower On Wednesday
U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday. Shares of Veradigm Inc. (NASDAQ: MDRX) shares fell sharply during Wednesday’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
The Latest Analyst Ratings For Mirum Pharmaceuticals
Via Benzinga
11 Analysts Have This to Say About Mirum Pharmaceuticals
Via Benzinga
Analyst Ratings for Mirum Pharmaceuticals
Via Benzinga
Earnings Outlook For Mirum Pharmaceuticals
Via Benzinga
Analyst Ratings for Mirum Pharmaceuticals
Via Benzinga
Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic... 
Via Benzinga
Analyst Ratings for Mirum Pharmaceuticals
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
Via Benzinga
7 Small-Cap Stocks That Get the Nod from Wall Street
Although small-cap stocks tend to be extremely risky, these compelling ideas just happen to get the nod from Wall Street analysts. 
Via InvestorPlace
Why Shares of Travere Therapeutics Are Slumping Thursday
A mixed trial could hurt a kidney drug's chances of full approval. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2023
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.